Local Anesthesia With Schelin Catheter in Rezum Treatment: a Randomized Controlled Trial
Recruiting now · Not applicable
Conditions studied: Benign Prostatic Hyperplasia
In brief
In a pilot study, water vapor therapy (RezumTM, Boston Scientific Corporation, Marlborough, MA) was proposed as a minimally invasive procedure for benign prostatic hyperplasia, but often requiring oral ± intravenous sedation or a transrectal prostatic block. Therefore, pain management during Rezum therapy remains a challenge and may lead to the use of pain control protocols and general anesthesia, limiting in some ways the concept of a minimally invasive ambulatory surgical approach. The Schelin® catheter (ProstaLund AB, Lund, Sweden), approved by the European Medicines Agency, is a device for injecting analgesic drugs directly into the prostate via the trans-urethral route, providing more effective local anesthesia and avoiding the need for transrectal route or general anesthesia. This catheter is therefore of crucial importance in offering to our patients an ultra-minimally invasive treatment, associated with a reduction in room occupancy time, outpatient surgery time, a procedure performed independently of the anesthesia team, and for the patient, an accelerated post-operative recovery. Our hypothesis is that the REZUM procedure under local anesthesia could be associated with a \>20% reduction in operating room occupancy time compared to procedures performed under general anesthesia.
Key facts
- Study ID
- NCT06657872
- Run by
- Assistance Publique Hopitaux De Marseille
- People needed
- 24
- Starts
- 2025-03-24
- Expected to finish
- 2026-11-24
- Last updated by the study team
- 2026-02-11
Who can join
Age: 18 and older, up to 80. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Patients referred for symptomatic benign prostatic hyperplasia (BPH)
- Men between 45 and 80 years of age
- IPSS > 13
- Qmax <15 ml/s
- Prostate volume between 30 and 80 g on ultrasound
- Patient able to understand study details, benefits and risks
- Patient able to give informed consent
- Beneficiary of or affiliated to the French social security system
- Patient having signed an informed consent form
You may not qualify if…
- Patients with a history of prostate cancer
- Patient with history of BPH surgery
- Patients with a history of neurological bladder disease
- Patient with history of urethral stricture
- Patient with history of penile implants
- Patient with history of pelvic irradiation
- Patient with a symptomatic urinary tract infection in the 10 days prior to surgery
- Presence of bladder stones on ultrasonography
- Patient allergic to lidocaine 2% or any medication used in the pre-operative protocol (anxiolytics, analgesics and non-steroidal anti-inflammatory drugs)
- Patient under guardianship or curatorship
- Protected patient, deprived of liberty
- Patient with a neurological and/or psychiatric disorder making it impossible to understand the terms of the study and to sign an informed consent form
Where it is running
- Service d'urologie, Hôpital Nord (AP-HM) — Marseille, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.